Overview

Phase 2b Study of GSK4532990 in Adults With NASH

Status:
Not yet recruiting
Trial end date:
2025-03-11
Target enrollment:
Participant gender:
Summary
The purpose of this study is to measure improvements in liver fibrosis and inflammation with GSK4532990 compared with placebo in participants with NASH and advanced (F3) fibrosis. The study duration will be up to 76 weeks including the screening period. The treatment duration will be up to 52 weeks.
Phase:
Phase 2
Details
Lead Sponsor:
GlaxoSmithKline